Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 27
Filtrer
1.
Cell Rep Med ; 4(2): 100912, 2023 02 21.
Article de Anglais | MEDLINE | ID: mdl-36669488

RÉSUMÉ

Medical artificial intelligence (AI) has been moving from the research phase to clinical implementation. However, most AI-based models are mainly built using high-quality images preprocessed in the laboratory, which is not representative of real-world settings. This dataset bias proves a major driver of AI system dysfunction. Inspired by the design of flow cytometry, DeepFundus, a deep-learning-based fundus image classifier, is developed to provide automated and multidimensional image sorting to address this data quality gap. DeepFundus achieves areas under the receiver operating characteristic curves (AUCs) over 0.9 in image classification concerning overall quality, clinical quality factors, and structural quality analysis on both the internal test and national validation datasets. Additionally, DeepFundus can be integrated into both model development and clinical application of AI diagnostics to significantly enhance model performance for detecting multiple retinopathies. DeepFundus can be used to construct a data-driven paradigm for improving the entire life cycle of medical AI practice.


Sujet(s)
Intelligence artificielle , Cytométrie en flux , Courbe ROC , Aire sous la courbe
2.
Drug Discov Ther ; 16(6): 313-315, 2022 Dec 26.
Article de Anglais | MEDLINE | ID: mdl-36529506

RÉSUMÉ

Cholestasis and obstructive jaundice can be extrahepatic or intrahepatic. Here we present one case with calculous cholecystitis who presenting with repeated obstructive jaundice and without bile duct dilation. The patient received laparoscopic cholecystectomy, and cystohepatic duct was identified intraoperatively, there was no cholestasis or obstructive jaundice postoperatively. Cystohepatic duct is a rare biliary anomaly observed in 0.7% of all surgical cases and in 1.5% of all cadaveric dissections. The cystohepatic duct can be the bridge of calculous cholecystitis complicating cholangitis and obstructive jaundice, here we for the first time presented this entity.


Sujet(s)
Angiocholite , Cholécystectomie laparoscopique , Cholécystite , Ictère rétentionnel , Humains , Ictère rétentionnel/étiologie , Ictère rétentionnel/chirurgie , Cholécystite/complications , Cholécystite/chirurgie , Angiocholite/complications , Angiocholite/chirurgie
3.
Aging (Albany NY) ; 13(4): 5069-5086, 2021 02 01.
Article de Anglais | MEDLINE | ID: mdl-33535174

RÉSUMÉ

CD4+ T cells are considered to be vital in chronic liver diseases, but their exact roles in hepatic capillarization, the typical characteristic of liver fibrosis, are poorly understood. This study aimed to assess the roles of typical subtype of CD4+ T cells, named T helper 1 (Th1) and Th2 cells in liver fibrosis. Taking advantage of well established fibrotic rat model, we conducted in vitro and in vivo experiments to explore the interactions between liver sinusoidal endothelial cells (LSECs) and Th1/2 cells; meanwhile we evaluated the degree of hepatic capillarization when inhibiting these interactions with inhibitory antibodies. Our results showed that prohibiting interactions between Th2 cells and LSECs caused the restoration of fenestrae, increased cytokine level of Th1 cells and reduction of hepatic capillarization; inhibiting the interaction between Th1 cells and LSECs produced the opposite effects. Moreover, increased Rho and myosin light chain phosphorylation were observed when Th1 cells were inhibited with the corresponding inhibitory antibody; Th2 cell inhibition yielded the opposite results. This study indicated that Th1/2 cells steer the capillarization process in different directions and this effect is probably mediated by the Rho-Rho kinase (ROCK)-myosin signaling pathway.


Sujet(s)
Vaisseaux capillaires/anatomopathologie , Cellules endothéliales/métabolisme , Cirrhose du foie/immunologie , Néovascularisation pathologique/immunologie , Lymphocytes auxiliaires Th1/immunologie , Lymphocytes auxiliaires Th2/immunologie , Amine oxidase (copper-containing)/antagonistes et inhibiteurs , Animaux , Vaisseaux capillaires/ultrastructure , Molécules d'adhérence cellulaire/antagonistes et inhibiteurs , Cytokines/immunologie , Cellules endothéliales/anatomopathologie , Cellules endothéliales/ultrastructure , Intégrine alpha4/antagonistes et inhibiteurs , Foie/immunologie , Foie/anatomopathologie , Foie/ultrastructure , Myosines/métabolisme , Néovascularisation pathologique/anatomopathologie , Rats , Transduction du signal , Protéines G rho/métabolisme , rho-Associated Kinases/métabolisme
4.
J Int Med Res ; 48(12): 300060520979224, 2020 Dec.
Article de Anglais | MEDLINE | ID: mdl-33334212

RÉSUMÉ

OBJECTIVE: Near-infrared fluorescence cholangiography (NIRF-C) can help to identify the bile duct during laparoscopic cholecystectomy. This retrospective study was performed to investigate the effect of NIRF-C in laparoscopic cholecystectomy. METHODS: Consecutive patients who underwent NIRF-C-assisted laparoscopic cholecystectomy (n = 34) or conventional laparoscopic cholecystectomy (n = 36) were enrolled in this study. Identification of biliary structures, the operation time, intraoperative blood loss, and postoperative complications were analyzed. RESULTS: Laparoscopic cholecystectomy was completed in all patients without conversion to laparotomy. The median operation time and intraoperative blood loss were not significantly different between the two groups. No intraoperative injuries or postoperative complications occurred in either group. In the NIRF-C group, the visualization rate of the cystic duct, common bile duct, and common hepatic duct prior to dissection was 91%, 79%, and 53%, respectively. The success rate of cholangiography was 100% in the NIRF-C group. NIRF-C was more effective for visualizing biliary structures in patients with a BMI of <25 than >25 kg/m2. CONCLUSIONS: NIRF-C is a safe and effective technique that enables real-time identification of the biliary anatomy during laparoscopic cholecystectomy. NIRF-C helps to improve the efficiency of dissection.


Sujet(s)
Cholangiographie , Cholécystectomie laparoscopique , Vert indocyanine , Adulte , Agents colorants , Femelle , Humains , Mâle , Adulte d'âge moyen , Études rétrospectives
5.
Gastroenterol Rep (Oxf) ; 7(5): 354-360, 2019 Oct.
Article de Anglais | MEDLINE | ID: mdl-31687155

RÉSUMÉ

BACKGROUND: Hepatocellular carcinoma (HCC) is frequently associated with metabolism dysfunction. Increasing evidence has demonstrated the crucial role of lipid metabolism in HCC progression. The function of apolipoprotein F (ApoF), a lipid transfer inhibitor protein, in HCC is incompletely understood. We aimed to evaluate the functional role of ApoF in HCC in this study. METHODS: We used quantitative reverse-transcription polymerase chain reaction (qRT-PCR) to detect ApoF mRNA expression in HCC tissues and hepatoma cell lines (SMMC-7721, HepG2, and Huh7). Immunohistochemistry was performed to detect the expression of ApoF in HCC tissues. The associations between ApoF expression and clinicopathological features as well as HCC prognosis were analyzed. The effect of ApoF on cellular proliferation and growth of SMMC-7721 and Huh7 cells was examined in vitro and in vivo. RESULTS: ApoF expression was significantly down-regulated at both mRNA and protein levels in HCC tissues as compared with adjacent tissues. In SMMC-7721 and Huh7 HCC cells, ApoF overexpression inhibited cell proliferation and migration. In a xenograft nude mouse model, ApoF overexpression effectively controlled HCC growth. Kaplan-Meier analysis results showed that the recurrence-free survival rate of HCC patients with low ApoF expression was significantly lower than that of other HCC patients. Low ApoF expression was associated with several clinicopathological features such as liver cirrhosis, Barcelona Clinic Liver Cancer stage and tumor-node-metastasis stage. CONCLUSIONS: ApoF expression was down-regulated in HCC, which was associated with low recurrence-free survival rate. ApoF may serve as a tumor suppressor in HCC and be a potential application for the treatment of this disease.

6.
World J Surg Oncol ; 17(1): 45, 2019 Mar 01.
Article de Anglais | MEDLINE | ID: mdl-30823932

RÉSUMÉ

BACKGROUND: The effect of antiviral therapy (AVT) on clinical outcomes in patients with hepatocellular carcinoma (HCC) who are seronegative for hepatitis B virus (HBV), defined as HBV DNA < 100 IU/ml prior to surgical resection, is unknown. The main purpose of this study was to evaluate the possible value of AVT in this cohort of patients. METHODS: From January 2006 to January 2013, 161 HCC patients with positive serum tests for HBV surface antigen (HBsAg) but negative tests for HBV DNA who had undergone hepatectomy were included and analyzed. Propensity score matching (PSM) was used to balance the heterogeneity in baseline characteristics. RESULTS: All patients were divided into the following two groups: the AVT group (n = 73, 45.34%) and the non-AVT group (n = 88, 54.66%). HBV reactivation occurred in 20 patients in the non-AVT group (22.73%) but in only 2 patients in the AVT group (2.74%, p < 0.001). After PSM, the 1-, 2-, and 3-year recurrence-free survival (RFS) rates in the AVT group and the non-AVT group were 78.38%, 72.97%, and 62.16% and 81.08%, 72.97%, and 72.97%, respectively (p = 0.564); the 1-, 2-, and 3-year overall survival (OS) rates were 97.30%, 97.3%, and 91.89% and 94.59%, 94.59%, and 86.49% in the AVT group and non-AVT group, respectively (p = 0.447). CONCLUSIONS: Antiviral therapy can reduce HBV reactivation but is not correlated with a significant increase in postoperative RFS and OS in HCC patients with HBV DNA levels < 100 IU/ml.


Sujet(s)
Antiviraux/usage thérapeutique , Carcinome hépatocellulaire/thérapie , Hépatectomie , Tumeurs du foie/thérapie , Activation virale/effets des médicaments et des substances chimiques , Antiviraux/pharmacologie , Carcinome hépatocellulaire/sang , Carcinome hépatocellulaire/mortalité , Carcinome hépatocellulaire/virologie , ADN viral/isolement et purification , Survie sans rechute , Femelle , Virus de l'hépatite B/effets des médicaments et des substances chimiques , Virus de l'hépatite B/génétique , Virus de l'hépatite B/isolement et purification , Humains , Foie/anatomopathologie , Foie/chirurgie , Foie/virologie , Tumeurs du foie/sang , Tumeurs du foie/mortalité , Tumeurs du foie/virologie , Mâle , Adulte d'âge moyen , Période postopératoire , Pronostic , Score de propension , Études rétrospectives , Facteurs de risque , Taux de survie
7.
Acta Biochim Biophys Sin (Shanghai) ; 51(1): 68-77, 2019 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-30566565

RÉSUMÉ

TRIM29 plays an important role in many neoplasms. In this study, we aimed to elucidate its role in hepatocellular carcinoma (HCC) and explore the corresponding potential mechanism. The expression level of TRIM29 in HCC samples and hepatoma cell lines was detected. We found that TRIM29 was down-regulated in clinical HCC samples and cultured hepatoma cell lines by western blot analysis and quantitative polymerase chain reaction. In addition, we demonstrated that higher TRIM29 expression was associated with higher differentiation grade of HCC. To explore the effect of TRIM29 on hepatoma cells and its possible mechanisms, TRIM29-knockdown and overexpression cell models were constructed. The results showed that the depletion of TRIM29 promoted liver cancer cell proliferation, clone formation, migration and invasion in vitro probably through the Wnt/ß-catenin signaling pathway. This study revealed the inhibitory roles of TRIM29 in HCC and the possible mechanisms.


Sujet(s)
Carcinome hépatocellulaire/génétique , Protéines de liaison à l'ADN/génétique , Régulation de l'expression des gènes tumoraux , Tumeurs du foie/génétique , Facteurs de transcription/génétique , Voie de signalisation Wnt/génétique , Carcinome hépatocellulaire/métabolisme , Carcinome hépatocellulaire/anatomopathologie , Lignée cellulaire tumorale , Mouvement cellulaire/génétique , Prolifération cellulaire/génétique , Protéines de liaison à l'ADN/métabolisme , Évolution de la maladie , Femelle , Cellules HepG2 , Humains , Tumeurs du foie/métabolisme , Tumeurs du foie/anatomopathologie , Mâle , Adulte d'âge moyen , Interférence par ARN , Facteurs de transcription/métabolisme
8.
J Huazhong Univ Sci Technolog Med Sci ; 37(6): 895-903, 2017 Dec.
Article de Anglais | MEDLINE | ID: mdl-29270750

RÉSUMÉ

Human Nestin (hNestin) has been found to express in melanoma, and its expression is positively correlated with the advanced stage of melanoma. However, the precise role of hNestin in the development of melanoma has not been fully understood. The present study aimed to explore the role of hNestin in the proliferation and invasion of melanoma cells. The lentivirus vector carrying a short hairpin RNAs (shRNAs) targeting hNestin (hNestin-shRNA-LV) was stably infected into human melanoma cells UACC903, which expressed high levels of hNestin. The effects of hNestin knockdown on the proliferation, apoptosis, migration of melanoma cells and the related signaling pathways were investigated by immunofluorence, Western blotting and reverse transcription polymerase chain reaction (RT-PCR), respectively. The results showed that hNestin was expressed in most melanoma specimens and the melanoma cells studied. Knockdown of hNestin expression significantly inhibited the proliferation of melanoma cells, blocked the formation of cell colony, arrested cell cycle at G1/S stage and suppressed the activation of Akt and GSK3ß. hNestin-silent cells also showed a sheet-like appearance with tight cell-cell adhesion, decreased membrane expression of N-cadherin and ß-catenin, and attenuated migration. Furthermore, hNestin silence resulted in the inhibition of tumor growth in vivo. Our study indicates that hNestin knockdown suppresses the proliferation of melanoma cells, which might be through affecting Akt-GSK3ß-Rb pathway-mediated G1/S arrest, and hNestin silence inhibits the migration by selectively modulating the expression of cell adhesion molecules in the process of epithelial-mesenchymal transition.


Sujet(s)
Régulation de l'expression des gènes tumoraux , Glycogen synthase kinase 3 beta/génétique , Mélanome/génétique , Nestine/génétique , Protéines proto-oncogènes c-akt/génétique , Protéine du rétinoblastome/génétique , Tumeurs cutanées/génétique , Antigènes CD/génétique , Antigènes CD/métabolisme , Apoptose , Cadhérines/génétique , Cadhérines/métabolisme , Lignée cellulaire tumorale , Mouvement cellulaire , Prolifération cellulaire , Transition épithélio-mésenchymateuse , Points de contrôle de la phase G1 du cycle cellulaire , Vecteurs génétiques/composition chimique , Vecteurs génétiques/métabolisme , Glycogen synthase kinase 3 beta/métabolisme , Humains , Lentivirus/génétique , Lentivirus/métabolisme , Mélanome/métabolisme , Mélanome/anatomopathologie , Mélanome/thérapie , Nestine/antagonistes et inhibiteurs , Nestine/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Petit ARN interférent/génétique , Petit ARN interférent/métabolisme , Protéine du rétinoblastome/métabolisme , Transduction du signal , Tumeurs cutanées/métabolisme , Tumeurs cutanées/anatomopathologie , Tumeurs cutanées/thérapie , Charge tumorale , Tests d'activité antitumorale sur modèle de xénogreffe , bêta-Caténine/génétique , bêta-Caténine/métabolisme
9.
World J Surg Oncol ; 15(1): 227, 2017 Dec 19.
Article de Anglais | MEDLINE | ID: mdl-29258518

RÉSUMÉ

BACKGROUND: It is generally accepted that an insufficient future liver remnant is a major limitation of large-scale hepatectomy for patients with primary hepatocellular carcinoma. Conventional two-stage hepatectomy (TSH) is commonly considered to accelerate future liver regeneration despite its low regeneration rate. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), which is characterized by a rapid regeneration, has brought new opportunities. METHODS: Relevant studies were identified by searching the selected databases up to September 2017. Then, a meta-analysis of regeneration efficiency, complication rate, R0 resection ratio, and short-term outcomes was performed. RESULTS: Ten studies, comprising 719 patients, were included. The overall analysis showed that ALPPS was associated with a larger hyperplastic volume and a shorter time interval (P < 0.00001) than TSH. ALPPS also exhibited a higher completion rate for second-stage operations (odds ratio, OR 9.50; P < 0.0001) and a slightly higher rate of R0 resection (OR 1.90; P = 0.11). Interestingly, there was no significant difference in 90-day mortality between the two treatments (OR 1.44; P = 0.35). CONCLUSIONS: These results indicate that compared with TSH, ALPPS possesses a stronger regenerative ability and better facilitates second-stage operations. However, the safety, patient outcomes, and patient selection for ALPPS require further study.


Sujet(s)
Carcinome hépatocellulaire/chirurgie , Hépatectomie/méthodes , Tumeurs du foie/chirurgie , Régénération hépatique , Complications postopératoires/épidémiologie , Carcinome hépatocellulaire/mortalité , Hépatectomie/effets indésirables , Humains , Ligature/effets indésirables , Ligature/méthodes , Foie/physiologie , Foie/chirurgie , Tumeurs du foie/mortalité , Sélection de patients , Veine porte/chirurgie , Complications postopératoires/étiologie , Pronostic , Résultat thérapeutique
10.
Intractable Rare Dis Res ; 6(3): 172-176, 2017 Aug.
Article de Anglais | MEDLINE | ID: mdl-28944138

RÉSUMÉ

Recurrent bile duct stones is the most common complication after gallstone surgery and the incidence is about 4-24%. Sphincter of Oddi laxity will lead to duodenal content flow into the bile or pancreatic duct. Patients with recurrent bile duct stones and Oddis sphincter laxity were intractable. Here we sought to present the possible and helpful surgical treatments for such patients. Prospective randomized clinical trial are needed for evaluating the outcome of surgical treatments.

11.
Biosci Trends ; 11(2): 163-168, 2017 May 23.
Article de Anglais | MEDLINE | ID: mdl-28250338

RÉSUMÉ

Because of the prevalence of viral hepatitis and nonalcoholic fatty liver disease (NAFLD), liver fibrosis has become a very common disease in Asia and elsewhere in the world, constantly increasing the burden of care borne by society. Hepatic sinusoidal capillarization, characterized by gradually shrinking fenestrae on the surface of liver sinusoidal endothelial cells (LSECs) and the formation of an organized basement membrane, is an initial pathologic change associated with liver fibrosis. Basic and clinical studies have indicated that LSECs play a key role in hepatic sinusoidal capillarization by affecting various aspects of the development and progression of liver fibrosis. Reviewing studies on the effect of LSECs on liver fibrosis is essential to better understanding the pathogenesis of liver fibrosis and its mechanism of progression. Moreover, such a review will provide a theoretical basis for identifying new methods to promote the regression or even inhibition of fibrosis. This review will focus on structural and functional changes in LSECs during hepatic sinusoidal capillarization and the interaction between the micro-environment of the liver and the body's immune system.


Sujet(s)
Cirrhose du foie/métabolisme , Animaux , Évolution de la maladie , Cellules endothéliales/cytologie , Cellules endothéliales/métabolisme , Humains , Foie/cytologie , Foie/métabolisme , Cirrhose du foie/anatomopathologie
12.
Article de Chinois | WPRIM (Pacifique Occidental) | ID: wpr-333407

RÉSUMÉ

Human Nestin (hNestin) has been found to express in melanoma,and its expression is positively correlated with the advanced stage of melanoma.However,the precise role of hNestin in the development of melanoma has not been fully understood.The present study aimed to explore the role of hNestin in the proliferation and invasion of melanoma cells.The lentivirus vector carrying a short hairpin RNAs (shRNAs) targeting hNestin (hNestin-shRNA-LV) was stably infected into human melanoma cells UACC903,which expressed high levels of hNestin.The effects of hNestin knockdown on the proliferation,apoptosis,migration of melanoma cells and the related signaling pathways were investigated by immunofluorence,Western blotting and reverse transcription polymerase chain reaction (RT-PCR),respectively.The results showed that hNestin was expressed in most melanoma specimens and the melanoma cells studied.Knockdown of hNestin expression significantly inhibited the proliferation of melanoma cells,blocked the formation of cell colony,arrested cell cycle at G1/S stage and suppressed the activation of Akt and GSK3β.hNestin-silent cells also showed a sheet-like appearance with tight cell-cell adhesion,decreased membrane expression of N-cadherin and β-catenin,and attenuated migration.Furthermore,hNestin silence resulted in the inhibition of tumor growth in vivo.Our study indicates that hNestin knockdown suppresses the proliferation of melanoma cells,which might be through affecting Akt-GSK3β-Rb pathway-mediated G1/S arrest,and hNestin silence inhibits the migration by selectively modulating the expression of cell adhesion molecules in the process of epithelial-mesenchymal transition.

13.
Dig Dis Sci ; 60(5): 1315-24, 2015 May.
Article de Anglais | MEDLINE | ID: mdl-25567052

RÉSUMÉ

BACKGROUND AND AIM: Hepatitis B virus core promoter (CP) mutations can increase risk of hepatocellular carcinoma. The CP region overlaps with the HBV X (HBx) gene, which has been associated with hepatocarcinogenesis. The cyclin kinase inhibitor P53 is an important regulator of cell cycle progression. We determined whether HBx mutants that result from mutations in the CP deregulate P53. METHODS: A HBx combination (combo) mutant with changes in the CP region that corresponded to A1762T/G1764A (TA), T1753A, and T1768A was constructed and expressed in L-02 and Hep3B cells. The effects of CP mutations on expression and degradation of P53, and the effects on cell cycle progression and proliferation were analyzed. RESULTS: The combo mutant decreased levels of P53 and increased cyclin D1 expression, accelerated P53 degradation in L-02 cells, accelerated cell cycle progression, and increased expression of S-phase kinase-associated protein 2 (Skp2) in L-02 and Hep3B cells. Silencing of Skp2 abrogated the effects of CP mutations on P53 expression. The kinetics of P53 expression correlated with changes in cell cycle distribution. CONCLUSIONS: The HBx mutant with a combination of CP mutations can up-regulate Skp2, which then down-regulates P53 via ubiquitin-mediated proteasomal degradation, increasing the risk of hepatocellular carcinoma.


Sujet(s)
Carcinome hépatocellulaire/virologie , Transformation cellulaire virale , Virus de l'hépatite B/génétique , Hépatite B/virologie , Tumeurs du foie/virologie , Mutation , Protéines associées aux kinases de la phase S/métabolisme , Transactivateurs/génétique , Protéine p53 suppresseur de tumeur/métabolisme , Protéines du core viral/génétique , Carcinome hépatocellulaire/génétique , Carcinome hépatocellulaire/métabolisme , Carcinome hépatocellulaire/anatomopathologie , Cycle cellulaire , Lignée cellulaire tumorale , Prolifération cellulaire , Cycline D1/métabolisme , Régulation de l'expression des gènes tumoraux , Génotype , Hépatite B/complications , Virus de l'hépatite B/pathogénicité , Humains , Tumeurs du foie/génétique , Tumeurs du foie/métabolisme , Tumeurs du foie/anatomopathologie , Phénotype , Proteasome endopeptidase complex/métabolisme , Protéolyse , Interférence par ARN , Protéines associées aux kinases de la phase S/génétique , Facteurs temps , Transfection , Protéine p53 suppresseur de tumeur/génétique , Ubiquitination , Protéines virales régulatrices ou accessoires
14.
World J Surg ; 39(5): 1142-9, 2015 May.
Article de Anglais | MEDLINE | ID: mdl-25270343

RÉSUMÉ

BACKGROUND: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death internationally, it is necessary to reappraise evidences of HCC cells involving the portal vein, especially considering tumor size. MATERIALS AND METHODS: Histopathological evidence and dynamic evidences of radiology and cytology from publication were collected and analyzed. RESULTS: Frequencies of microscopic portal vein involvement (MPVI) and microscopic intrahepatic metastasis (MIM) in resected specimens with single nodule HCC were lower than that of multi nodule HCC, although not significantly. Early HCC (≤1.5 cm) was with extremely low to 0 frequencies of MPVI and MIM. HCC >5 cm showed a tendency of flowing HCC cells into portal vein, which was coincident with significantly high frequency (64.1 %) of MPVI for HCC >5 cm. There were no significant difference of frequencies of MPVI and MIM between groups of tumor ≤2, ≤3, and ≤5 cm. CONCLUSIONS: Single nodule HCC >5 cm needs anatomic resection and the root of portal vein should be firstly ligated because of tendency of flowing HCC cells into portal vein. For single nodule HCC ≤2 cm, there was a risk of about 16.2 % of MPVI, and a risk of about 16.2-26.4 % of MPVI for those single nodule HCC ≤5 cm, however, there was a risk of extremely low to 0 of MPVI for early HCC (≤1.5 cm). Surgeons have to balance liver reserve and risk of MPVI for HCC ≤5 cm before deciding anatomic or nonanatomic resection.


Sujet(s)
Carcinome hépatocellulaire/anatomopathologie , Tumeurs du foie/anatomopathologie , Veine porte/anatomopathologie , Carcinome hépatocellulaire/secondaire , Carcinome hépatocellulaire/chirurgie , Hépatectomie , Humains , Ligature , Tumeurs du foie/secondaire , Tumeurs du foie/chirurgie , Invasion tumorale , Micrométastase tumorale , Cellules tumorales circulantes , Veine porte/chirurgie , Charge tumorale
15.
Exp Biol Med (Maywood) ; 240(2): 156-9, 2015 Feb.
Article de Anglais | MEDLINE | ID: mdl-25135987

RÉSUMÉ

Although percutaneous radio frequency ablation for hepatocellular carcinoma is a minimally invasive therapy, there are some complications reported; major complications include hemorrhage (0.477%), hepatic injuries (1.690%), and extrahepatic organ injuries (0.691%). We, for the first time, described a rare complication of delayed bronchobiliary fistula and cholangiolithiasis in common bile duct following radio frequency ablation and the salvage treatment in a patient with chronic hepatitis B virus infection. Surgeons should be aware of severe and rare complications before deciding the ablation area and when performing radio frequency ablation, and should be aware of the relevant salvage treatment.


Sujet(s)
Fistule biliaire , Carcinome hépatocellulaire/chirurgie , Ablation par cathéter/effets indésirables , Calculs biliaires , Hépatite B chronique/chirurgie , Tumeurs du foie/chirurgie , Complications postopératoires/anatomopathologie , Fistule biliaire/étiologie , Fistule biliaire/anatomopathologie , Fistule bronchique/étiologie , Fistule bronchique/anatomopathologie , Carcinome hépatocellulaire/anatomopathologie , Calculs biliaires/étiologie , Calculs biliaires/anatomopathologie , Hépatite B chronique/anatomopathologie , Humains , Tumeurs du foie/anatomopathologie , Mâle , Adulte d'âge moyen
16.
Biosci Trends ; 8(3): 185-8, 2014 Jun.
Article de Anglais | MEDLINE | ID: mdl-25030854

RÉSUMÉ

Primary hepatic mucosa-associated lymphoid tissue (MALT) lymphoma has a low incidence and is a rare subtype of hepatic malignant lymphoma. Described here is a rare case of primary hepatic MALT lymphoma and hepatic hemangioma with chronic HBV infection as an underlying condition. Possible treatment modalities, which should be selected in accordance with tumor size, tumor location, tumor number, and underlying liver disease, are discussed in conjunction with a review of the literature. In addition, the potential use of hepatic resection, radio frequency ablation (RFA), or radiotherapy followed by chemotherapy via the R-CHOP regimen is also discussed.


Sujet(s)
Hémangiome/diagnostic , Hépatite B chronique/diagnostic , Tumeurs du foie/diagnostic , Lymphome B de la zone marginale/diagnostic , Hémangiome/étiologie , Hépatite B chronique/complications , Humains , Tumeurs du foie/étiologie , Lymphome B de la zone marginale/étiologie , Mâle , Adulte d'âge moyen
17.
Cytotherapy ; 15(10): 1266-74, 2013 Oct.
Article de Anglais | MEDLINE | ID: mdl-23993301

RÉSUMÉ

BACKGROUND AIMS: Assessing mesenchymal stromal cells (MSCs) after grafting is essential for understanding their migration and differentiation processes. The present study sought to evaluate via cellular magnetic resonance imaging (MRI) if transplantation route may have an effect on MSCs engrafting to fibrotic liver of rats. METHODS: Rat MSCs were prepared, labeled with superparamagnetic iron oxide and scanned with MRI. Labeled MSCs were transplanted via the portal vein or vena caudalis to rats with hepatic fibrosis. MRI was performed in vitro before and after transplantation. Histologic examination was performed. MRI scan and imaging parameter optimization in vitro and migration under in vivo conditions were demonstrated. RESULTS: Strong MRI susceptibility effects could be found on gradient echo-weighted, or T2∗-weighted, imaging sequences from 24 h after labeling to passage 4 of labeled MSCs in vitro. In vivo, MRI findings of the portal vein group indicated lower signal in liver on single shot fast spin echo-weighted, or T2-weighted, imaging and T2∗-weighted imaging sequences. The low liver MRI signal increased gradually from 0-3 h and decreased gradually from 3 h to 14 days post-transplantation. The distribution pattern of labeled MSCs in liver histologic sections was identical to that of MRI signal. It was difficult to find MSCs in tissues near the portal area on day 14 after transplantation; labeled MSCs appeared in fibrous tuberculum at the edge of the liver. No MRI signal change and a positive histologic examination were observed in the vena caudalis group. CONCLUSIONS: The portal vein route seemed to be more beneficial than the vena caudalis on MSC migration to fibrotic liver of rats via MRI.


Sujet(s)
Fibrose/diagnostic , Foie/imagerie diagnostique , Imagerie par résonance magnétique/méthodes , Transplantation de cellules souches mésenchymateuses , Cellules souches/métabolisme , Animaux , Tétrachloro-méthane/administration et posologie , Différenciation cellulaire , Mouvement cellulaire , Cellules cultivées , Composés du fer III/métabolisme , Fibrose/induit chimiquement , Fibrose/thérapie , Foie/anatomopathologie , Mâle , Veine porte/imagerie diagnostique , Veine porte/métabolisme , Scintigraphie , Rats , Rat Wistar , Cellules souches/imagerie diagnostique , Cellules souches/anatomopathologie
18.
Drug Discov Ther ; 7(4): 164-6, 2013 Aug.
Article de Anglais | MEDLINE | ID: mdl-24071579

RÉSUMÉ

Postoperative recurrence of hepatocellular carcinoma (HCC) has a negative impact on long-term survival. According to available evidence, many systemic untargeted agents are ineffective as adjuvant therapy to prevent the recurrence of HCC following curative resection. Interferon α has potential effectiveness as adjuvant therapy for HCC in the presence of underlying conditions such as HBV or HCV infection. Oral polyprenoic acid has also proven its effectiveness according to a prospective study; however, no other studies have reported polyprenoicacid (acyclic retinoid) to be effective. Sorafenib is the only systemic molecular targeted agent that has proven effectiveness as adjuvant therapy according to a pilot study. To date, 11 randomized clinical trials are underway with different agents as adjuvant systemic drug therapy to prevent the recurrence of HCC following curative resection according to Clinicaltrial.gov. Adjuvant systemic drugs may be the most promising of all adjuvant modalities in the near future since HCC may be a systemic disease rather than a local disease.


Sujet(s)
Antinéoplasiques/usage thérapeutique , Carcinome hépatocellulaire/traitement médicamenteux , Carcinome hépatocellulaire/chirurgie , Hépatectomie , Tumeurs du foie/traitement médicamenteux , Tumeurs du foie/chirurgie , Récidive tumorale locale/prévention et contrôle , Carcinome hépatocellulaire/secondaire , Traitement médicamenteux adjuvant , Humains , Tumeurs du foie/anatomopathologie , Thérapie moléculaire ciblée , Récidive tumorale locale/anatomopathologie , Résultat thérapeutique
19.
Exp Biol Med (Maywood) ; 238(8): 866-73, 2013 Aug 01.
Article de Anglais | MEDLINE | ID: mdl-23828588

RÉSUMÉ

This study aimed to retrospectively investigate the expression of the phosphate and tension homologue deleted on chromosome 10 (PTEN) protein and its prognostic role in hepatocellular carcinoma (HCC) with family aggregation resulting from hepatitis B and liver cirrhosis, which have not been established. Immunohistochemical analysis was performed to evaluate the PTEN protein expression in HCC and paired para-cancerous tissues from 79 patients with HCC caused by hepatitis B and liver cirrhosis. Of these cases, 34 represented HCC with family aggregation (HCCF group), and 45 represented HCC with no family aggregation (HCCN group). Follow-up data were collected for 3 months to 10 years and analysed for HCC recurrence, survival time and prognostic risk factors. The expression of the PTEN protein in the HCC tissue was dramatically lower in the HCCF group than in the HCCN group. The six-month, one-year and two-year overall recurrence (OR) rates of the HCCF group were significantly higher than those of the HCCN group. The one-year, two-year and five-year overall survival (OS) rates of the HCCF group were lower than those of the HCCN group. Impaired PTEN protein expression was an independent prognostic risk factor that was significantly correlated with OR and OS in HCC patients. Dramatically impaired PTEN protein expression in HCC patients with family aggregation resulting from hepatitis B and liver cirrhosis was correlated with OR and OS, and impaired PTEN expression was an independent risk factor for prognosis after radical surgery.


Sujet(s)
Marqueurs biologiques tumoraux/métabolisme , Carcinome hépatocellulaire/étiologie , Carcinome hépatocellulaire/chirurgie , Hépatite B/complications , Cirrhose du foie/complications , Tumeurs du foie/étiologie , Tumeurs du foie/chirurgie , Phosphohydrolase PTEN/métabolisme , Adulte , Marqueurs biologiques tumoraux/génétique , Carcinome hépatocellulaire/mortalité , Évolution de la maladie , Femelle , Études de suivi , Régulation de l'expression des gènes tumoraux , Hépatectomie , Humains , Incidence , Tumeurs du foie/mortalité , Mâle , Adulte d'âge moyen , Analyse multifactorielle , Récidive tumorale locale/épidémiologie , Phosphohydrolase PTEN/génétique , Pronostic , Études rétrospectives , Facteurs de risque , Taux de survie
20.
Biosci Trends ; 7(1): 7-12, 2013 Feb.
Article de Anglais | MEDLINE | ID: mdl-23524888

RÉSUMÉ

China has one of the world's highest rates of hepatitis B infection. Over the past 20 years, a series of strategies have been implemented to prevent infection with the hepatitis B virus (HBV) in China. These strategies include hepatitis B (hepB) immunization for susceptible populations such as infants and young children and for high-risk populations such as health care workers and patients, premarital health care for couples of childbearing age, and standard medical practices. A series of measures implemented by the Chinese government caused the HBV infection rate in China to decrease from 9.75% in 1992 to 7.2% in 2006. However, a report on infectious diseases indicated that more than 1 million people in China were infected with hepB in 2011. There is room for improvement. The current work analyzed the current status of and challenges for strategies to prevent HBV infection in China. This work also recommends clear guidance regarding hepB immunization for parents in rural areas, more flexible premarital health care, health education for both patients and health care workers, and routine HBV screening for high-risk health care workers.


Sujet(s)
Vaccins anti-hépatite B/usage thérapeutique , Hépatite B/prévention et contrôle , Dépistage de masse , Adulte , Enfant , Chine/épidémiologie , Femelle , Hépatite B/diagnostic , Hépatite B/immunologie , Humains , Nourrisson , Nouveau-né , Mâle , Facteurs de risque
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE